Corporate Update: China National Accord Medi
The Shenzhen‑listed pharmacy and healthcare services firm, China National Accord Medi (000028.SZ), closed its most recent trading session unchanged, with its share price remaining flat at 0 % over the 24‑hour period ending at 05:15 PM Central Europe on Thursday, 22 October. At the close, the stock traded at CNY 20.58, a figure that sits slightly above its 200‑day simple moving average of CNY 20.3.
Market Snapshot
- Current supply: 562.6 million shares
- Market capitalisation: CNY 11.6 billion
- Volume traded in last 24 h: CNY 111.5 million worth of shares
- 52‑week high: CNY 25.72 (24 October 2025)
- 52‑week low: CNY 18.70 (29 June 2026)
- Year‑to‑date change since month‑end: +3.17 %
Despite the flat intraday movement, the firm’s share price has maintained a modest upward trajectory relative to the end of the previous month, signalling a degree of investor confidence amid ongoing market volatility.
Recent Earnings Report
China National Accord Medi has just released a preliminary financial statement covering the first three quarters of 2026. The company’s key highlights are:
| Metric | FY‑Q3 2026 | FY‑Q3 2025 | YoY Change |
|---|---|---|---|
| Total revenue | slight decline | – | – |
| Net profit for shareholders | modest decline | – | – |
| Adjusted net profit (ex. non‑recurring items) | small rise | – | – |
| Q3 revenue growth | positive | – | – |
| Q3 adjusted profit | significant increase | – | – |
A deeper dive into the segment performance shows that:
- Distribution revenue remained largely flat, indicating a stable channel but limited expansion.
- Retail operations posted a modest revenue increase while achieving a substantial rise in profitability, suggesting operational efficiencies and stronger margins.
Management emphasized that the company is actively fortifying its core activities, broadening its market footprint, and optimizing its product mix. They noted that the recent contraction in revenue has narrowed and that profit growth has begun to resume, albeit with a caveat that these figures are provisional and will be subject to final audit adjustments.
Peer Performance (Last 24 h)
| Stock | Ticker | Change | Current Price | Market Cap | P/E (if available) |
|---|---|---|---|---|---|
| Beijing Teamsun | 600410.SS | 0 % | CNY 12.8 | CNY 13.8 bn | – |
| Shenzhen Kangtai Biologica | 300601.SZ | 0 % | CNY 12.01 | CNY 13.8 bn | 157.7 |
| China Marine Information I | 600764.SS | 0 % | CNY 19.39 | CNY 13.9 bn | 169.84 |
| Jonjee High‑Tech Industria | 600872.SS | 0 % | CNY 17.53 | CNY 13.8 bn | 19.66 |
| Beijing Relpow | 300593.SZ | 0 % | CNY 26.51 | CNY 13.8 bn | – |
All peer stocks exhibited a flat 24‑hour performance, mirroring the broader stability observed across the Shenzhen market segment.
Company Profile
China National Accord Medicines Corp. Ltd. is a diversified healthcare provider headquartered in Shenzhen. Its operations span the development and manufacture of pharmaceuticals, wholesaling and retailing of patent and traditional Chinese medicines, biological products, healthcare items, and medical instruments. The firm first entered the public markets on 5 May 1993 and remains listed on the Shenzhen Stock Exchange. More detailed information can be accessed on the company’s website at www.szaccord.com.cn .
This article provides a concise yet comprehensive overview of China National Accord Medi’s recent market activity, earnings outlook, and peer context, catering to investors and industry observers seeking a clear understanding of the company’s current standing.
